Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data
- PMID: 18362252
- DOI: 10.1001/archinte.168.6.598
Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data
Erratum in
- Arch Intern Med. 2008 May 26;168(10):1089
- Arch Intern Med. 2008 May 26;168(10):1096
Abstract
Background: Large-scale prospective data are needed to determine whether associations between lipoprotein(a) (Lp[a]) and coronary heart disease (CHD) risk are independent of established risk factors, to characterize the shape of this relationship, and to quantify associations in relevant subgroups.
Methods: Levels of Lp(a) were measured in samples obtained at baseline from 2047 patients who had first-ever nonfatal myocardial infarction or who died of CHD during the study and from 3921 control participants in the Reykjavik Study (n=18 569), as well as in paired samples obtained 12 years apart from 372 participants to quantify within-person fluctuations.
Results: Baseline Lp(a) levels had little or no correlation with known cardiovascular risk factors, such as age, sex, total cholesterol level, and blood pressure. The Lp(a) values were highly consistent from decade to decade, with a regression dilution ratio (calculated on the log scale) of 0.92 (95% confidence interval, 0.85-0.99). The odds ratio for CHD, unaltered after adjustment for several established risk factors (age, sex, smoking status, blood pressure, total cholesterol, triglycerides level, diabetes mellitus, and body mass index), was 1.60 (95% confidence interval, 1.38-1.85) in a comparison of extreme thirds of baseline Lp(a) levels. Odds ratios were progressively higher with increasing Lp(a) levels and did not vary materially by several individual- or study-level characteristics.
Conclusions: There are independent, continuous associations between Lp(a) levels and risk of future CHD in a broad range of individuals. Levels of Lp(a) are highly stable within individuals across many years and are only weakly correlated with known risk factors. Further assessment of their possible role in CHD prevention is warranted.
Similar articles
-
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2902-8. doi: 10.1161/ATVBAHA.113.302479. Epub 2013 Oct 3. Arterioscler Thromb Vasc Biol. 2013. PMID: 24092750 Clinical Trial.
-
[Elevated levels of lipoprotein(a) are present in subjects with early ischemic cardiopathy and with a familial history of ischemic cardiopathy].Minerva Med. 1999 May-Jun;90(5-6):151-8. Minerva Med. 1999. PMID: 10780189 Clinical Trial. Italian.
-
Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease.Eur J Cardiovasc Prev Rehabil. 2003 Oct;10(5):362-70. doi: 10.1097/01.hjr.0000087080.83314.be. Eur J Cardiovasc Prev Rehabil. 2003. PMID: 14663298
-
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063. JAMA. 2009. PMID: 19622820 Free PMC article. Review.
-
Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors.Curr Opin Cardiol. 1999 Mar;14(2):186-91. doi: 10.1097/00001573-199903000-00017. Curr Opin Cardiol. 1999. PMID: 10191979 Review.
Cited by
-
Cholesterol crystals in the pathogenesis of atherosclerosis.Nat Rev Cardiol. 2024 Nov 18. doi: 10.1038/s41569-024-01100-3. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 39558130 Review.
-
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry.J Am Heart Assoc. 2024 May 21;13(10):e034493. doi: 10.1161/JAHA.123.034493. Epub 2024 May 18. J Am Heart Assoc. 2024. PMID: 38761082 Free PMC article.
-
Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on Alzheimer's disease.Heliyon. 2024 Mar 7;10(8):e27422. doi: 10.1016/j.heliyon.2024.e27422. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38644883 Free PMC article.
-
Joint Association of Lipoprotein(a) and a Family History of Coronary Artery Disease with the Cardiovascular Outcomes in Patients with Chronic Coronary Syndrome.J Atheroscler Thromb. 2024 Sep 1;31(9):1319-1332. doi: 10.5551/jat.64693. Epub 2024 Apr 13. J Atheroscler Thromb. 2024. PMID: 38616111 Free PMC article.
-
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?Int J Mol Sci. 2024 Mar 21;25(6):3537. doi: 10.3390/ijms25063537. Int J Mol Sci. 2024. PMID: 38542510 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
